companies / step-ph-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-08 json
| total_raised | 2,700,0002.7M | ○ |
|---|---|---|
| founded | null | |
| hq | Saint-Genis-Pouilly, France | |
| industry | unknown | |
| stage | null |
STEP Pharma develops dencatistat (STP938), a first-in-class oral CTPS1 inhibitor designed to treat T-cell lymphomas, B-cell lymphomas, solid tumors, and essential thrombocythaemia. It targets oncology patients in cancers where survival has stagnated for decades, especially peripheral T-cell lymphoma. Most advanced selective CTPS1 inhibitor in clinical development.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-04-01 | grant | 2,700,0002.7M | null | ○ |
Nginx, WordPress 7.0, Yoast SEO 27.6, Slider Revolution, jQuery Migrate 3.4.1, imagesLoaded 5.0.0, PHP, MySQL, jquery 3.
| fact | status | src |
|---|---|---|
| Grant, $2.7M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |